biotech · Leber Congenital Amaurosis 10 · Sickle Cell Disease · EDIT
Editas Medicine
Editas Medicine is a biotech organization headquartered in Cambridge, USA. It trades on NYSE under ticker EDIT. Primary therapeutic focus areas include Leber Congenital Amaurosis 10, Sickle Cell Disease, Transfusion Depe
Cambridge, USA HQ
2013 Founded
183 Employees
Public company Type
EDIT · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2013
- Employees
- 183
- Programs
- 3
- Drugs
- 1
- Patents
- 21
EDIT-301
Phase 2 · gene therapy · Transfusion Dependent Beta Thalassemia
EDIT-301 for Transfusion Dependent Beta Thalassemia is a Phase 2 program (gene_therapy) at Editas Medicine with 1 ClinicalTrials.gov record(s).
Internal code EM-301-BThal-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Editas Medicine
- Phase
- Phase 2
- Modality
- gene_therapy
- Indication
- Transfusion Dependent Beta Thalassemia
- Status
- active
- Trials
- 1